Cancer prevention research 2010; 15(4): 340-346
Published online December 30, 2010
© Korean Society of Cancer Prevention
Ji Hyun Kim1, Sun Young Chae1, Jae Soo Choi2, Jong-Hwan Lee3 and Kwang-Hyeon Kim1
This study was aimed at identifying a cytotoxic compound on human acute lymphoma jurkat T cells from bark of Albizzia julibrissin Durazz and determining its synergistic effect with doxorubicin. The partially purified substance from A. julibrissin, HaBC18, was further purified through recycling HPLC chromatography. The purified cytotoxic substance of A. julibrissin was estimated to have about 94.5% purity by analytical HPLC and designated "Ha75F1". Chemical structure of the Ha75F1 was analyzed with Mass spectrum, 1H-NMR, 13C-NMR, HMBC and HMQC spectrum. The Ha75F1 is identified as Julibroside III. Its molecular formula is 12C10313CH164NO48 and its molecular weight is 2,219Da. The mixture with Julibroside III and doxorubicin led to enhanced cytotoxic effect on jurkat T cell. In conclusion, the Julibroside III purification method from A. julibrissin was established and its strong cytotoxicity was evaluated. The mixture of Julibroside III and doxorubicin represented stronger anticancer activity than each compound on jurkat T cell. Thus, this material has great potential as an anti-tumor agent, health promotion or tonic agent. (Cancer Prev Res 15, 340-346, 2010)
Keywords: Albizzia julibrissin Durazz, cytotoxicity, jurkat T cell, Julibroside III, Doxorubicin
Ajay Kumar Raj, Kiran Bharat Lokhande, Kratika Khunteta, Sachin Chakradhar Sarode, Nilesh Kumar Sharma
J Cancer Prev 2024; 29(2): 32-44 https://doi.org/10.15430/JCP.24.002Young Ran Ha, In-Ae Lee, Hyo Jung Kim, Hee Jung Kang, Dae Hwan Nam, Jia Parkand Jong-Sang Kim
Cancer prevention research 2010; 15(1): 45-51Gun-Ae Yoon, Seon Yeong Chae and Kwang-Hyeon Kim
Cancer prevention research 2012; 17(3): 239-243